Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: Challenges and opportunities

Current Opinion in Oncology

Volumn 23, Issue 5, 2011, Pages 463-468

  Krown, Susan E ^a  

^a Rockville MA ^*  (United States)

Author keywords

Aids Associated Cancer; Chemotherapy; Hiv Aids; Kaposi Sarcoma; Sub Saharan Africa

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; BLEOMYCIN; DOXORUBICIN; GEMCITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CANCER DIAGNOSIS; CANCER REGRESSION; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KAPOSI SARCOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE; VIRUS LOAD;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOMA, KAPOSI;

EID: 80051988914     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328349428d     Document Type: Review

References (37)

1. Bagni R, Whitby D. Kaposi's sarcoma-associated herpesvirus transmission and primary infection. Curr Opin HIV AIDS 2009; 4:22-26.
2. Mosam A, Aboobaker J, Shaik F. Kaposi's sarcoma in sub-Saharan Africa: a current perspective. Curr Opin Infect Dis 2010; 23:119-123.
3. Biryahwaho B, Dollard SC, Pfeiffer RM, et al. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. J Infect Dis 2010; 202:1347-1353.
4. Malope-Kgokong BI, Macphail P, Mbisa G, et al. Kaposi's sarcoma associated-herpes virus (KSHV) seroprevalence in pregnant women in South Africa. Infect Agent Cancer 2010; 5:14.
5. Caterino-de-Araujo A, Manuel RC, Del Bianco R, et al. Seroprevalence of human herpesvirus 8 infection in individuals from healthcare centers in Mozambique: potential for endemic and epidemic Kaposi's sarcoma. J Med Virol 2010; 82:1216-1223.
6. Sasco AJ, Jaquet A, Boidin E, et al. The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One 2010; 5:e8621.
7. Lemma E, Constantine NT, Kassa D, et al. Human herpesvirus 8 infection in HIV-1-infected and uninfected pregnant women in Ethiopia. Ethiop Med J 2009; 47:205-211.
8. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer 2010; 126:1187-1195.
9. Mosam A, Carrara H, Shaik F, et al. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006). Int J STD AIDS 2009; 20:553-556.
10. Butler LM, Dorsey G, Hladik W, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis 2009; 200:430-438.
11. Mosam A, Hurkchand HP, Cassol E, et al. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. Int J STD AIDS 2008; 19:400-405.
12. Malope BI, MacPhail P, Mbisa G, et al. No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. AIDS 2008; 22:519-526. (Pubitemid 351317294)
13. Bihl F, Mosam A, Henry LN, et al. Kaposi's sarcoma-associated herpesvirusspecific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 2007; 21:1245-1252. (Pubitemid 46883478)
14. Lin L, Lee J, Kaplan L, et al. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 2009; 27:2496-2502.
15. Mosam A, Shaik F, Uldrick TS, et al. The KAART Trial: a randomized controlled trial of HAART compared to the combination of HAART and chemotherapy in treatment-naẗve patients with HIV-associated Kaposi sarcoma (HIV-KS) in KwaZulu-Natal (KSN) South Africa. 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI). Bethesda, MD, April 26-27, 2010. Abstract 09, page 39. Three abstracts presented at international meetings in 2010 that provide response, safety and quality of life data from the only prospectively randomized trial of HAART with chemotherapy in treatment-naẗve HIV\+ patients with Kaposi sarcoma in KwaZulu-Natal South Africa.
16. Mosam A, Shaik F, Uldrick TS, et al. HART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi's sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial. 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI). Bethesda, MD, April 26-27, 2010. Abstract 47, page 117. Three abstracts presented at international meetings in 2010 that provide response, safety and quality of life data from the only prospectively randomized trial of HAART with chemotherapy in treatment-naẗve HIV\+ patients with Kaposi sarcoma in KwaZulu-Natal South Africa.
17. Mosam A, Shaik F, Uldrick T, et al. The KAART Trial: a randomised controlled trial of HAART compared to the combination of HAART and chemotherapy in treatment naive patients with HIV-associated Kaposi's Sarcoma (HIV-KS) in KwaZulu-Natal (KZN), South Africa NCT 00380770, in: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Paper #32.
18. Sissolak G, Mayaud P. AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med International Health 2005; 10:981-992. (Pubitemid 41445062)
19. Mlombe Y. Management of HIV associated Kaposi's sarcoma in Malawi. Malawi Med J 2008; 20:129-132.
20. Strother RM, Gregory KM, Pastakia S, et al. Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in Western Kenya. Oncology 2010; 78:5-11.
21. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. J Clin Oncol 1989; 7:1201-1207. (Pubitemid 19220121)
22. Gantt S, Kakuru A, Wald A, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer 2010; 54:670-674.
23. Cairncross LL, Davidson A, Millar AJ, Pillay K. Kaposi sarcoma in children with HIV: a clinical series from Red Cross Children's Hospital. J Pediatr Surg 2009; 44:373-376.
24. Ramdial PK, Sing Y, Hadley GP, et al. Paediatric intussusception caused by acquired immunodeficiency syndrome-associated Kaposi sarcoma. Pediatr Surg Int 2010; 26:783-787.
25. Casper C. The increasing burden of HIV-associated malignancies in resourcelimited regions. Ann Rev Med 2011; 62:157-170.
26. Goldman JD, Mutyaba I, Okuku F, et al. Measurement of the impact of antiretroviral therapy coverage on incidence of AIDS-defining malignancies in sub-Saharan Africa. Abstract. Lancet 2011 [published online March 14]. doi: 10.1016/S0140-6736(11)60169-4.
27. Mosam A, Uldrick T, Shaik F, et al. Availability of highly active antiretroviral therapy improves the ability to treat Kaposi's sarcoma in South Africa. Int J STD and AIDS (in press).
28. Borok M, Fiorillo S, Gudza I, et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis 2010; 51:342-349.
29. Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005; 113:632-639. (Pubitemid 40038741)
30. Chu KM, Mahlangeni G, Swannet S, et al. AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J International AIDS Soc 2010; 13: 23-27.
31. Makombe SD, Harries AD, Yu JK, et al. Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doct 2008; 38:5-7.
32. Letang E, Almeida JM, Miro JM, et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in Mozambique: a prospective study. J Acquir Immune Defic Syndr 2010; 53:589-597.
33. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Last accessed 4/24/2011.
34. Sitas F, Parkin DM, Chirenje M, et al. Part II: cancer in indigenous Africans: causes and control. Lancet Oncol 2008; 9:786-795. (Pubitemid 352038317)
35. Orem J, Wabinga H. The roles of national cancer research institutions in evolving a comprehensive cancer control program in a developing country: experience from Uganda. Oncology 2009; 77:272-280.
36. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of lowand middle income: a call to action. Lancet 2010; 376:1186-1193.
37. Kerr DJ, Midgley R. Can we treat cancer for a dollar a day? Guidelines for lowincome countries. N Engl J Med 2010; 363:801-803.